Benchmark Holdings plc (BHCCF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 2.14 means the share price is 2.14 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $225M is the value of all shares combined. Beta 0.27: the stock has moved about 73% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBenchmark Holdings plc (BHCCF) trades at $0.3658. Benchmark Holdings plc provides technical services, products, and specialist knowledge to support the food and farming industries. Market cap: $225M, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BHCCF: BHCCF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BHCCF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Dated analysis: the newest financial statements on file are 24 months old (Sep 1, 2024), so the figures and score below describe that period, not today.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
BHCCF: 1/2 scored disciplines lean bullish. Dominant signal: Ken Griffin bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Benchmark Holdings plc (BHCCF) Healthcare & Pipeline Overview
Benchmark Holdings plc, founded in 2000, provides genetics, advanced nutrition, and health solutions to the aquaculture industry globally. With a market capitalization of $225M, the company focuses on breeding technologies, nutrition products, and health products like Ectosan Vet and CleanTreat for sea lice, operating across Europe, Asia, and the Americas.
What Is the Investment Thesis for BHCCF?
With a market capitalization of $225M and a P/E ratio of 2.14, the company demonstrates profitability, supported by a gross margin of 43.1% and a substantial profit margin of 278.5%. Key value drivers include the increasing demand for sustainable aquaculture practices and the growing need for effective disease management solutions like Ectosan Vet and CleanTreat. Growth catalysts include expanding its genetics offerings and penetrating new geographic markets. Potential risks include regulatory changes and competition within the aquaculture industry. The company's beta of 0.27 suggests lower volatility compared to the market.
Based on FMP financials and quantitative analysis
BHCCF Key Highlights
Market capitalization of $225M indicates a moderate-sized player in the aquaculture industry.
- P/E ratio of 2.14 suggests the company is potentially undervalued compared to its earnings.
- Profit margin of 278.5% highlights strong profitability and efficient operations.
- Gross margin of 43.1% indicates a healthy ability to control production costs.
- Beta of 0.27 suggests lower volatility compared to the overall market, making it a potentially stable investment.
Who Are BHCCF's Competitors?
BHCCF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CPHRF Cipher Pharmaceuticals Inc. | $10.50 | +0.96% | $267M | — |
| MAYNF Mayne Pharma Group Limited | $2.35 | 0.00% | $191M | — |
| CRDL Cardiol Therapeutics Inc. | $1.98 | -13.35% | $228M | 605-pillar |
| SIGA SIGA Technologies, Inc. | $3.04 | +0.83% | $218M | 355-pillar |
| TSNDF TerrAscend Corp. | $0.64 | -7.84% | $237M | 499-signal |
| CBWTF Auxly Cannabis Group Inc. | $2.37 | +0.85% | $243M | 549-signal |
| ORGO Organogenesis Holdings Inc. | $1.53 | -2.55% | $197M | 375-pillar |
| CRLBF Cresco Labs Inc. | $0.73 | -4.21% | $258M | 459-signal |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are BHCCF's Key Strengths?
Integrated approach offering genetics, nutrition, and health solutions.
- Proprietary breeding technologies and intellectual property.
- Global presence and established customer relationships.
- Strong profitability and efficient operations.
What Are BHCCF's Weaknesses?
Reliance on the aquaculture industry, which is subject to environmental and regulatory risks.
- Potential for disease outbreaks to impact customer demand.
- Exposure to currency fluctuations due to international operations.
- Limited brand recognition compared to larger competitors.
What Could Drive BHCCF Stock Higher?
Expansion of the Genetics segment through new breeding technologies.
- Increasing demand for sustainable aquaculture practices driving growth in the Advanced Nutrition segment.
- Potential regulatory approvals for new health solutions in key markets.
- Strategic partnerships and acquisitions to expand market reach.
- Growing global demand for seafood driving overall growth in the aquaculture industry.
What Are the Key Risks for BHCCF?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 5 reported quarters.
- Regulatory changes impacting aquaculture practices and product approvals.
- Disease outbreaks affecting customer demand and production.
- Increasing competition from established and emerging players in the aquaculture industry.
- Exposure to currency fluctuations due to international operations.
- Economic downturns affecting demand for aquaculture products.
What Are the Growth Opportunities for BHCCF?
- Expansion of Genetics Segment: Benchmark can further expand its genetics segment by developing new breeding technologies for additional aquaculture species and enhancing the genetic merit of existing species. The global aquaculture genetics market is projected to reach $2.5 billion by 2028, presenting a significant opportunity for Benchmark to increase its market share through strategic partnerships and research and development initiatives. Timeline: Ongoing.
- Geographic Expansion: Benchmark has the opportunity to expand its geographic footprint, particularly in emerging aquaculture markets in Asia and South America. These regions are experiencing rapid growth in aquaculture production, driven by increasing demand for seafood and favorable regulatory environments. Entering these markets would require strategic partnerships and localized product offerings. Timeline: 2-3 years.
- Development of New Health Solutions: Benchmark can invest in the development of new health solutions to address emerging disease challenges in aquaculture. The aquaculture health market is estimated at $3 billion annually, with a growing need for innovative treatments and preventative measures. Focus areas could include vaccines, diagnostics, and sustainable disease management strategies. Timeline: 3-5 years.
- Strategic Acquisitions: Benchmark can pursue strategic acquisitions to expand its product portfolio and geographic reach. Acquiring companies with complementary technologies or market access would accelerate Benchmark's growth and strengthen its competitive position. Potential targets could include companies specializing in aquaculture nutrition, health, or genetics. Timeline: Ongoing.
- Enhanced Data Analytics and Precision Farming: Benchmark can leverage data analytics and precision farming technologies to optimize aquaculture production and improve efficiency for its customers. By collecting and analyzing data on genetics, nutrition, and health, Benchmark can provide valuable insights and recommendations to help farmers improve yields, reduce costs, and minimize environmental impact. Timeline: 1-2 years.
What Are BHCCF's Competitive Advantages?
- Proprietary breeding technologies for key aquaculture species.
- Strong brand reputation and established customer relationships.
- Integrated approach offering genetics, nutrition, and health solutions.
- Regulatory approvals and intellectual property protection for key products.
What Does BHCCF Do?
Benchmark Holdings plc, established in 2000 and headquartered in Sheffield, UK, operates as a key player in providing technical services, products, and specialist knowledge to the food and farming industries. The company's operations are divided into three core segments: Genetics, Advanced Nutrition, and Health. The Genetics segment focuses on breeding technologies for sea bass, bream, salmon, shrimp, and tilapia, offering genetically improved ova to enhance production efficiency and quality. The Advanced Nutrition segment manufactures and supplies nutrition and health products tailored for the aquaculture industry, ensuring optimal growth and health for farmed species. The Health segment provides innovative health solutions, including Ectosan Vet and CleanTreat, designed to combat sea lice infestations in aquaculture, a significant challenge for the industry. Benchmark Holdings has a global presence, operating in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, and other parts of Europe and internationally, serving a diverse range of customers within the aquaculture sector.
What Products and Services Does BHCCF Offer?
- Provides breeding technologies for sea bass, bream, salmon, shrimp, and tilapia.
- Manufactures and supplies nutrition products for the aquaculture industry.
- Offers health products, including Ectosan Vet and CleanTreat, for sea lice control.
- Develops and markets genetically improved ova to enhance aquaculture production.
- Provides technical services and specialist knowledge to support the food and farming industries.
- Operates globally, serving customers in Europe, Asia, and the Americas.
- Focuses on sustainable aquaculture practices and disease management solutions.
How Does BHCCF Make Money?
- Generates revenue through the sale of genetically improved ova to aquaculture farmers.
- Earns revenue from the sale of nutrition and health products to the aquaculture industry.
- Provides technical services and consulting to aquaculture operations.
- Focuses on recurring revenue streams through long-term customer relationships and product subscriptions.
What Industry Does BHCCF Operate In?
Benchmark Holdings plc operates within the aquaculture industry, a sector experiencing significant growth due to increasing global demand for seafood and the need for sustainable protein sources. The industry is characterized by technological advancements in genetics, nutrition, and health management. Competitors include companies like AquaBounty Technologies (ABTI), which focuses on genetically engineered salmon, and other players in aquaculture health and nutrition. Benchmark's integrated approach, offering genetics, nutrition, and health solutions, positions it uniquely within this competitive landscape.
Who Are BHCCF's Key Customers?
- Aquaculture farmers raising sea bass, bream, salmon, shrimp, and tilapia.
- Aquaculture feed manufacturers.
- Aquaculture health service providers.
- Governmental and non-governmental organizations involved in aquaculture research and development.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 529 days ago
- ● No analyst coverage
- ● Reported in GBP, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 41 |
| 2026-08-26 | 41 |
| 2026-08-29 | 41 |
| 2026-09-01 | 41 |
| 2026-09-04 | 41 |
| 2026-09-07 | 41 |
| 2026-09-10 | 41 |
What changed?
The score has stayed at 41.
Over the same 18 days the stock moved +0.0%.
Company Profile
Benchmark Holdings plc operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Sheffield, GB. The company is led by CEO Patrick Waty. BHCCF has traded publicly since 2018.
Benchmark Holdings plc Financial Trajectory
Benchmark Holdings plc (BHCCF) reported $31.0M in revenue for Q2 FY2025, reflecting 29.2% growth compared to the prior quarter. The company recorded net income of $116.9M, with diluted EPS of $0.16. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, BHCCF averaged $0.02 in diluted EPS.
How Benchmark Holdings plc Is Valued
Benchmark Holdings plc carries a market capitalization of $225M, placing it in the micro-cap category.
Key Financial Metrics
Return on equity for Benchmark Holdings plc stands at 29.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 18.0%, showing how much profit it generates from its asset base. BHCCF trades at a trailing price-to-earnings ratio of 2.14, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 0.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 46.8%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Benchmark Holdings plc's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.83 places it in the grey zone, a middle ground that warrants monitoring.
Earnings Track Record
Benchmark Holdings plc has missed Wall Street's EPS estimate in 5 of its last 5 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 1626.1% below estimates on average.
Forward Outlook
Wall Street analysts project Benchmark Holdings plc revenue of about $86.5M for fiscal 2026, with EPS near $0.01.
BHCCF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Integrated approach offering genetics, nutrition, and health solutions.
- Proprietary breeding technologies and intellectual property.
- Global presence and established customer relationships.
- Strong profitability and efficient operations.
Bear Case
- Reliance on the aquaculture industry, which is subject to environmental and regulatory risks.
- Potential for disease outbreaks to impact customer demand.
- Exposure to currency fluctuations due to international operations.
- Limited brand recognition compared to larger competitors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2025 | $31M | $117M | $0.16 |
| Q1 FY2025 | $24M | -$13M | -$0.02 |
| Q4 FY2024 | -$28M | -$28M | -$0.04 |
| Q3 FY2024 | $41M | -$13M | -$0.02 |
Q2 FY2025 · filed 31 Mar 2025 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from GBP at today's rate
BHCCF Latest News
-
Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021
· Mar 2, 2021
-
Kepler Cheuvreux Upgrades Benchmark Holdings to Buy
· Mar 2, 2021
BHCCF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BHCCF.
Price Targets
Wall Street price target analysis for BHCCF.
BHCCF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BHCCF; grades run from A+ (80-100) to F (below 30).
Leadership: Patrick Waty
CEO
Patrick Waty serves as the CEO of Benchmark Holdings plc, leading a team of 800 employees. His background includes extensive experience in the aquaculture and animal health industries. Prior to joining Benchmark, Waty held leadership positions at various multinational corporations, focusing on strategic planning, business development, and operational excellence. He holds an MBA from a leading business school and a degree in veterinary medicine.
Track Record: Under Patrick Waty's leadership, Benchmark Holdings plc has focused on expanding its global presence and strengthening its product portfolio. Key achievements include the successful launch of new health solutions, such as Ectosan Vet and CleanTreat, and the expansion of the company's genetics segment. Waty has also overseen strategic acquisitions and partnerships to enhance Benchmark's competitive position.
BHCCF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Benchmark Holdings plc (BHCCF) may not meet the minimum financial or regulatory requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be penny stocks, or be experiencing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to stocks listed on major exchanges like the NYSE or NASDAQ due to the lack of stringent listing standards and regulatory oversight.
- OTC Tier: OTC Other
- Limited liquidity and potential for price manipulation due to lower trading volumes.
- Lack of stringent regulatory oversight and financial reporting requirements.
- Higher risk of fraud or company failure compared to stocks listed on major exchanges.
- Potential for delisting or suspension of trading due to non-compliance with OTC market rules.
- Information scarcity and difficulty in obtaining reliable financial data.
- Verify the company's financial statements and audit reports.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Review the company's legal and regulatory filings.
- Evaluate the company's capital structure and debt levels.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor before investing.
- Established operations in multiple countries, including the UK, Norway, and Chile.
- Focus on providing essential products and services to the aquaculture industry.
- Partnerships with reputable organizations and research institutions.
- Intellectual property protection for key products and technologies.
- Positive customer reviews and testimonials.
BHCCF Healthcare Stock FAQ
Is BHCCF a good stock?
Stock Expert AI does not rate BHCCF buy, sell or hold. Benchmark Holdings plc has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about BHCCF stock?
Generally, analysts consider factors such as the company's growth prospects in the aquaculture industry, its financial performance, and competitive positioning. Key valuation metrics include the P/E ratio, profit margin, and gross margin. A neutral summary would require the pending AI analysis.
What are the key factors to evaluate for BHCCF?
Evaluate BHCCF on fundamentals, analyst consensus, and risk factors. P/E: 2.14x vs the S&P 500's ~20-25x. The company's beta of 0.27 suggests lower volatility compared to the market. Not financial advice.
How frequently does BHCCF data refresh on this page?
BHCCF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BHCCF's recent stock price performance?
Benchmark Holdings plc (BHCCF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Integrated approach offering genetics, nutrition, and health solutions. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BHCCF overvalued or undervalued right now?
Benchmark Holdings plc (BHCCF) trades at 2.14x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BHCCF?
Yes, most major brokerages offer fractional shares of Benchmark Holdings plc (BHCCF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BHCCF's earnings and financial reports?
Benchmark Holdings plc (BHCCF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BHCCF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recently available information.
- The OTC analysis is based on general information about the OTC market and may not reflect specific details about BHCCF's compliance or disclosure status.